^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Simulect (basiliximab)

    i
    Other names: CHI 621, Chimeric RFT5, chRFT5, SDZ CHI 621, CHI-621, CHI621
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    CD25 inhibitor
    Related drugs:
    Associations

    News

    Trials
    25d
    SIMPLE: Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (clinicaltrials.gov)
    P4, N=20, Terminated, University of Southern California | N=80 --> 20 | Recruiting --> Terminated; Research contract expired
    Enrollment change • Trial termination
    |
    prednisone • Simulect (basiliximab)
    29d
    Stem Cell Transplantation for Patients With Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Completed, University of Chicago | Active, not recruiting --> Completed | N=15 --> 30
    Trial completion • Enrollment change
    |
    melphalan • Simulect (basiliximab) • plerixafor
    2ms
    Impact of Induction Therapy in Low Immunological Risk Simultaneous Pancreas-Kidney Transplantation. (PubMed, Transpl Int)
    These results were maintained even after IPTW adjustment. In SPKT recipients with low immunological risk, basiliximab provides comparable long-term patient and graft outcomes to thymoglobulin while reducing the incidence of opportunistic infections.
    Retrospective data • Journal
    |
    IL2 (Interleukin 2)
    |
    Simulect (basiliximab)
    3ms
    ONSET: 1 vs 7 RATG Infusions in Renal Transplantation (clinicaltrials.gov)
    P=N/A, N=75, Active, not recruiting, Mario Negri Institute for Pharmacological Research | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Simulect (basiliximab)
    4ms
    Induction Therapy with ATLG in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation Following Preoperative Immune Checkpoint Inhibitor Treatment: A Prospective, Multicenter, Randomized Controlled Trial (ChiCTR2500106702)
    P=N/A, N=220, Not yet recruiting, Huashan hospital affiliated to Fudan university; Huashan hospital affiliated to Fudan university
    New trial • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Simulect (basiliximab)
    5ms
    90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=12 --> 7
    Enrollment closed • Enrollment change
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • IL2RA (Interleukin 2 receptor, alpha) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    IL2RA expression
    |
    melphalan • fludarabine IV • Kepivance (palifermin) • Simulect (basiliximab)
    8ms
    MERRLIN: Impact of the Microbiota on the Likelihood of Renal Graft Rejection (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, Institut National de la Santé Et de la Recherche Médicale, France | Not yet recruiting --> Recruiting | Trial completion date: Sep 2024 --> Jan 2027 | Trial primary completion date: Sep 2023 --> Jan 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Simulect (basiliximab)
    9ms
    Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=25, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> May 2024
    Trial completion • Trial completion date
    |
    CD34 (CD34 molecule)
    |
    cytarabine • etoposide IV • carmustine • melphalan • Simulect (basiliximab)
    9ms
    Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    ALK (Anaplastic lymphoma kinase) • CD34 (CD34 molecule)
    |
    cytarabine • etoposide IV • etoposide oral • carmustine • melphalan • Simulect (basiliximab)
    11ms
    90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=12, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Jun 2027 | Trial primary completion date: Dec 2024 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • IL2RA (Interleukin 2 receptor, alpha) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    MLL rearrangement • IL2RA expression
    |
    melphalan • fludarabine IV • Kepivance (palifermin) • Simulect (basiliximab)
    1year
    Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients (clinicaltrials.gov)
    P2, N=67, Completed, Astellas Pharma Global Development, Inc. | Phase classification: P2a --> P2
    Phase classification
    |
    prednisone • Simulect (basiliximab)
    1year
    ONSET: 1 Vs 7 RATG Infusions in Renal Transplantation (clinicaltrials.gov)
    P=N/A, N=75, Recruiting, Mario Negri Institute for Pharmacological Research | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Simulect (basiliximab)